G Levy

A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Roy Fleischmann, Henning Bliddal, Francisco J. Blanco et al. · Arthritis & Rheumatology · 2019 · 211 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

M. Kloppenburg, Charles Peterfy, I.K. Haugen et al. · Annals of the Rheumatic Diseases · 2018 · 169 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

OP0168 A phase 2a, placebo-controlled, randomized study of ABT-981, an anti-interleukin-1ALPHA and -1BETA dual variable domain immunoglobulin, to treat erosive hand osteoarthritis (EHOA)

M. Kloppenburg, C. Peterfy, I.K. Haugen et al. · Annals of the Rheumatic Diseases · 2017 · 12 citations · Full text

Medicine, Immunology, Pharmacotherapy +16

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis

Séverine Vermeire, Silvio Danese, Wen Zhou et al. · Journal of Crohn s and Colitis · 2022 · 12 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12